文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗联合伊匹木单抗治疗转移性葡萄膜黑色素瘤:单臂II期研究结果

Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
PubMed 文献 · J Clin Oncol · 2020-10-30

这项单臂II期研究评估纳武利尤单抗联合伊匹木单抗治疗转移性葡萄膜黑色素瘤,允许既往任意线数治疗。联合方案显示出活性并有深度持久确认缓解。

要点

  • 纳武利尤单抗联合伊匹木单抗在转移性葡萄膜黑色素瘤中客观缓解率为18%。
  • 中位无进展生存期5.5个月,中位总生存期19.1个月。

核心结论

  • 纳武利尤单抗联合伊匹木单抗在转移性葡萄膜黑色素瘤中显示出活性,并有深度且持久的确认缓解。

研究设计与样本

  • 治疗方案为纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg共4周期,后续纳武利尤单抗维持治疗最长2年。
  • 主要终点为按RECIST 1.1标准评估的客观缓解率,同时评估无进展生存期、总生存期和不良事件。

主要发现

  • 客观缓解率为18%,包括1例确认完全缓解和5例确认部分缓解。
  • 中位无进展生存期为5.5个月(95% CI,3.4至9.5个月)。
  • 中位总生存期为19.1个月(95% CI,9.6个月至NR)。

关键数值与推荐

  • 客观缓解率18%,基于33例可评估患者的RECIST 1.1评估。
  • 中位无进展生存期5.5个月(95% CI,3.4至9.5个月)。
  • 中位总生存期19.1个月(95% CI,9.6个月至NR)。

临床怎么用

  • 对于转移性葡萄膜黑色素瘤患者,可考虑纳武利尤单抗联合伊匹木单抗作为系统治疗选择之一。
  • 治疗期间需密切监测3-4级治疗相关不良事件,及时处理毒性。

局限性

  • 允许既往任意线数治疗,患者基线异质性可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic therapy options. Studies of single-agent immunotherapy regimens have shown minimal benefit. There is the potential for improved responses with the use of combination immunotherapy. PATIENTS AND METHODS: We conducted a phase II study of nivolumab with ipilimumab in patients with metastatic uveal melanoma. Any number of prior treatments was permitted. Patients received nivolumab 1 mg/kg and ipilimumab 3 mg/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years. The primary outcome of the study was overall response rate (ORR) as determined by RECIST 1.1 criteria. Progression-free survival (PFS), OS, and adverse events were also assessed. RESULTS: Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy. The ORR was 18%, including one confirmed complete response and five confirmed partial responses. The median PFS was 5.5 months (95% CI, 3.4 to 9.5 months), and the median OS was 19.1 months (95% CI, 9.6 months to NR). Forty percent of patients experienced a grade 3-4 treatment-related adverse event. CONCLUSION: The combination regimen of nivolumab plus ipilimumab demonstrates activity in metastatic uveal melanoma, with deep and sustained confirmed responses.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pelster MS, Gruschkus SK, Bassett R, et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol. 2020. PMID: 33125309. doi:10.1200/JCO.20.00605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。